Frontlight ResearchEarly access
CompletedPhase 3
Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis
Key facts
- Who runs it
- Dr. Falk Pharma GmbH
- Where
- Austria, Denmark, Finland, France, Germany, Hungary, Netherlands, Norway, and Poland25 sites in 9 countriesChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 195 people enrolled
- Started
- 6 Dec 2017
- Ended
- 26 Mar 2026
- Type of study
- Interventional
- Record updated
- 5 May 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Signed informed consent
- Males or females
- Verified PSC
- Liver biopsy available
- Women of child-bearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile, who are sexually active have to apply a highly effective method of birth Control with a low failure rate (i.e., less than 1% per year) when used constantly and correctly such as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner, or sexual abstinence (only accepted as a highly effective contraceptive measure if it is the usual and preferred lifestyle of the patient), throughout the treatment period and for four weeks following the last dose of study drug. Hormonal methods other than levonorgestrel containing devices or medroxyprogesterone injections should be supplemented with use of a male condom. Women of non-childbearing potential may be included if surgically sterile or post-menopausal for at least 2 years. The investigator is responsible for determining whether the patient has this adequate birth control for study participation
Who cannot take part
- History or presence of other concomitant liver diseases including
- Participation in another clinical trial within the last 30 days prior to screening visit
- Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder, which in the opinion of the investigator might have an influence on the patient's compliance or on the interpretation of the results, or patient with atrial fibrillation or any disorder which in the opinion of the investigator may affect the patient's safety
- Imprisoned persons, persons admitted to nursing homes, persons under legal guardianship, and persons not able to express their consent (e.g. due to mental impairment)
- Any known relevant infectious disease (e.g., active tuberculosis, AIDS defining diseases)
- Any active malignant disease
- Known intolerance/hypersensitivity to study drug, or drugs of similar chemical structure or pharmacological profile
- Total bilirubin > 4.0 mg/dL (> 68 μmol/L) at screening or baseline
- Thyroid-stimulating hormone (TSH) > ULN at screening (elevated levels [4.2-10 μU/mL] are acceptable if fT4 is measured and within the normal range)
- Well-founded doubt about the patient's cooperation
- Existing or intended pregnancy or breast-feeding
- Patients who have an absolute contraindication for liver biopsy
- Secondary causes of Sclerosing Cholangitis
- Abnormal renal function
This trial has no sites in United States.
It has sites in 9 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To show the superiority of norursodeoxycholic acid (norUDCA) compared to placebo in the treatment of Primary Sclerosing Cholangitis (PSC) with regard to prevention of disease progression.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 5 May 2026